The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

BST2 overexpression decreased RSV multiplication. by Katherine Marougka (13015146)

A prepubertal CD decreases fat mass accumulation and prevents lean mass loss in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

Metformin and ZLN005 facilitate increased phagocytic uptake and intracellular killing of MAB. by Joel R. Frandsen (20685133)

Subjects:

TH5487 decreases RSV replication in lungs. by Lang Pan (5145221)

Annual trends in the volumes of open and minimally invasive colostomy reversal, 2012-2022. The proportion of minimally invasive procedures significantly increased over the study pe... by Kevin Tabibian (21601494)

Analyze data. by Xinhui Zhang (1624039)

Subjects:

Mouse spinal cord injury strike parame. by Xinhui Zhang (1624039)

Subjects:

NeuN expression and neuronal apoptosis in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Constructing the T10 spinal cord injury model. by Xinhui Zhang (1624039)

Subjects:

Expression of NeuN and CIRBP proteins in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Expression of IBA1 and CIRBP proteins in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease. by Emir Matpan (21655811)

“…Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease.…”

Distribution of the same ingredient across different IDDSI levels (Percentages and frequencies) and statistical significance analysis (Chi-square analysis). by Muxi Chen (9294270)

Subjects: